Highest-materiality recent filing
Issued amended warrant to accredited investor for 17,391,304 unvested shares at $0.23 exercise price.
Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track
Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.
Calidi Biotherapeutics issues warrant for 17.4M shares at $0.23 in private placement
Warrant to purchase up to 17,391,304 shares of common stock at $0.23 per share issued to accredited investor.
Director Allan J. Camaisa will not stand for re-election; term expires at 2026 annual meeting; no disagreement with company.
Calidi Biotherapeutics Q4 net loss $4.1M; FY net loss $25.6M; CLD-401 IND on track for end-2026
Q4 net loss $4.1M ($0.57/sh); FY net loss $25.6M ($5.95/sh) vs $23.8M ($35.70/sh) in 2024.
Calidi closes $6M public offering; existing warrants amended to $0.50 exercise price
Gross proceeds of $6.03M from 12,094,631 units sold (including full over-allotment exercise).
Calidi Biotherapeutics posts updated corporate presentation; details unknown
Company made updated presentation available on its website on February 6, 2026.
Calidi Biotherapeutics provides corporate update; debt reduced by $3.1M, IND planned for Q4 2026
Term debt and notes payable reduced to $0.7M at Dec 31, 2025, from $3.8M at Dec 31, 2024 (unaudited).
Calidi Biotherapeutics reports Q3 net loss of $5.2M; cash at $10.4M after $6.9M offering
Net loss $5.2M in Q3 2025; net loss attributable to shareholders $10.8M due to non-cash deemed dividend on warrants.
Calidi presents positive preclinical data on CLD-401 at SITC; IND filing expected by end 2026
CLD-401 protected from immune clearance and replicates specifically in tumor cells after systemic administration.
Sold 22.5M shares (100% of its Nova Cell ownership) for $6M; consideration includes debt cancellation of ~$1.2M and deferred payments.
Calidi Biotherapeutics forms Scientific Advisory Board to advance RedTail platform and CLD-401
SAB members include Drs. Mace Rothenberg (ex-Pfizer CMO), Dmitriy Zamarin (Mount Sinai), John Wrangle (MUSC), David Curiel (WashU).
Calidi eliminates CLO role; W. Pizarro Campbell departs Oct 17, 2025
CLO position eliminated; Campbell's employment terminated Oct 17, 2025 as part of cost-reduction initiatives; no disagreement cited.
Calidi Bio posts updated corporate presentation; no specifics available
Company made an updated presentation available on its website on August 29, 2025.
Calidi Biotherapeutics closes $6.9M public offering with full over-allotment exercise
Gross proceeds of $6.9M from 1,922,764 common stock units and 1,528,000 pre-funded warrant units.
Dr. Boris Minev ceased as President, Medical & Scientific Affairs and Section 16 officer effective July 29, 2025.
Calidi Q2 net loss narrows to $5.7M; FDA Fast Track for CLD-201; raises $4.6M
Net loss $5.7M ($1.99/share) vs $7.4M ($16.75/share) in Q2 2024; R&D $2.6M, G&A $3.1M.
Calidi Biotherapeutics effects 1-for-12 reverse stock split effective August 4, 2025
Reverse stock split at ratio 1-for-12 became effective on August 4, 2025.
Calidi eliminates President role; approves 1-for-12 reverse stock split effective Aug 5, 2025
Calidi eliminated the President, Medical & Scientific Affairs position held by Dr. Boris Minev, effective July 29, 2025; CMO Dr. Guy Travis Clifton assumes duties.
Calidi shareholders approve reverse stock split and 3M-share equity plan increase
Elected James Schoeneck (6.5M for) and George Peoples (6.6M for) as Class II directors.
Calidi Biotherapeutics raises $4.6M via warrant exercise at $0.70/share
Gross proceeds ~$4.6M from immediate exercise of 6,595,000 warrants at $0.70/share.
Calidi reports Q1 net loss $5.0M; CEO transition to Eric Poma; FDA clears CLD-201 IND
CEO transition: Eric Poma appointed CEO; 30+ yrs biopharma; raised >$250M at Molecular Templates.
Calidi Biotherapeutics replaces auditor Marcum with CBIZ after Marcum acquisition
Marcum resigned as independent auditor on April 30, 2025, following its acquisition by CBIZ.
Calidi appoints Eric Poma as CEO; Allan Camaisa resigns, remains director
Allan Camaisa resigned as CEO and Chairman, effective April 21, 2025; will stay as Class III director and CEO Emeritus.
Appointment effective April 8, 2025; one-year term with monthly consulting fee of $20,833.33.
Calidi Biotherapeutics closes $3.9M registered direct offering and private placement
Gross proceeds ~$3.9M from sale of 3.325M shares at $0.65 and pre-funded warrants for 2.728M shares.
Calidi Biotherapeutics reports Q4 net loss of $4.1M; files IND for CLD-201 solid tumor trial
Q4 2024 net loss $4.1M ($0.27/share) vs $8.2M loss ($0.23/share) in Q4 2023.
RTNova platform demonstrated killing of over 60 different tumor cell lines in preclinical models.
Calidi Biotherapeutics files 8-K/A to add auditor consent to Jan 10 filing
Amendment solely adds Exhibit 23.1, consent of Marcum LLP.
Calidi Biotherapeutics ups ATM offering capacity to $11.2M, adds $6.1M
Increased maximum ATM offering from $5.1M to $11.2M under existing sales agreement.
Calidi Biotherapeutics terminates SEPA with Yorkville; year-end cash $9.6M
Terminated Standby Equity Purchase Agreement with Yorkville effective Jan 23, 2025; no shares ever issued under $25M facility.
Calidi Biotherapeutics prices $4.25M public offering of 5M shares at $0.85/share
Priced public offering of 5,000,000 shares at $0.85 per share for gross proceeds of $4.25 million.
Calidi refiles FY2023 financials to reflect 1-for-10 reverse stock split
1-for-10 reverse stock split effective July 15, 2024, retroactively applied to FY2023 statements.
Calidi presents RTNova data supporting systemic targeting of metastatic lung cancer at IOVC and SITC
Data presented at IOVC and SITC shows RTNova enveloped virotherapy can target multiple metastatic tumor sites.
Calidi Biotherapeutics closes $7.5M public offering of 4.44M shares at $1.69/share
Gross proceeds ~$7.5M from 4,437,869 shares at $1.69; closed Nov 15, 2024.
Calidi Biotherapeutics Q3 net loss widens to $5.1M; FDA clears NeuroNova IND
Net loss of $5.1M ($0.65/share) vs. $2.0M ($1.41/share) in Q3 2023.
Calidi Biotherapeutics raises $2M in registered direct offering and private placement of warrants
Sold 2,050,000 shares at $1.00 per share in a registered direct offering.
NYSE American to delist Calidi Biotherapeutics warrants due to low trading price
NYSE Regulation commences delisting of Calidi warrants (CLDI WS) under Section 1001 of NYSE American Company Guide.
Calidi Biotherapeutics posts updated corporate presentation on its website
Calidi Biotherapeutics made an updated corporate presentation available on its website on October 18, 2024.
Calidi Biotherapeutics enters $5.1M ATM equity offering with Ladenburg Thalmann
Company may sell up to $5.1M of common stock through ATM facility with Ladenburg Thalmann.
FDA clears IND for Calidi's CLD-101 Phase 1b/2 trial in high-grade glioma
FDA cleared Northwestern University's IND for CLD-101, a stem cell-based oncolytic virus therapy for high-grade glioma.
Calidi Biotherapeutics elects Alan Stewart as director, ratifies auditor at annual meeting
Quorum of 57.57% (4,641,839 shares) present at Sep 20, 2024 annual meeting.
Calidi Biotherapeutics posts presentation on antitumor virotherapies after RedChip webinar
Presentation titled 'Systemic and Localized Antitumor Virotherapies' referenced during September 11, 2024 RedChip webinar.
Calidi Biotherapeutics posts presentation on new wholly owned subsidiary Redtail Biopharma
Presentation made available August 22, 2024 on company website.
Director George Ng to step down at 2024 annual meeting; Board reduced to 5
George Ng will allow his director term to expire at the Company's 2024 annual shareholder meeting.
Net loss of $5.8M ($1.40 per share) vs. $12.5M loss ($14.24 per share) in Q2 2023.
Dr. Ronald Rigor invests $1M in Calidi via 698,812 shares at $1.431 and warrants for 600,000 shares at $1.90.
Calidi Biotherapeutics announces 1-for-10 reverse stock split effective July 15, 2024
Reverse stock split at a 1-for-10 ratio, effective 12:01 a.m. ET on July 15, 2024.
Calidi Biotherapeutics secures $600K loan at 15% interest from Dennis Conklin
Loan agreement with Dennis R. Conklin for principal amount of $600,000.
Calidi Biotherapeutics announces 1-for-10 reverse stock split effective July 15, 2024
Reverse stock split at 1-for-10 ratio effective 12:01 a.m. ET on July 15, 2024.
the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Poma to serve as a Class I director of the Company, also effective April 22, 2025
Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
the Board, by a unanimous vote, appointed Eric Poma, Ph.D. to serve as CEO of the Company, effective April 22, 2025.
Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
On August 16, 2024, Mr. George Ng, a member of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”), informed the Board that, in order to focus on increasing professional commitments outside of the Company, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of the Company’s 2024 annual shareholder meeting.
On June 20, 2024, the Board of Directors (the “Board) of Calidi Biotherapeutics, Inc. (the “Company”) appointed Dr. George Peoples as a director, effective July 1, 2024.
On May 10, 2024, Mr. David LaPre notified the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as a director of the Company, including his position on each Board committee on which he served, effective immediately.
Max materiality 0.80 · Median 0.55 · Most common event other_material